Lyxor Stoxx Eurp 600 IndGd&Sv ETF AccA/I (INDP)

2.1100 -0.0700 (-3.21%) At close: 04:00PM EDT

Lyxor Stoxx Eurp 600 IndGd&Sv ETF AccA/I

Three Columbus Circle
15th Floor
New York, NY 10019
United States
646 427 2727
https://indaptusrx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 7

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Jeffrey A. Meckler	CEO & Director	888.32k	N/A	1967
Mr. Walt Addison Linscott Esq.	Chief Operating Officer	666.63k	N/A	1961
Dr. Michael J. Newman Ph.D.	Founder, Chief Scientific Officer & Director	468.82k	N/A	1956
Mr. Nir Sassi	CFO, Secretary & Treasurer	378.47k	N/A	1976
Dr. Roger J. Waltzman M.B.A., M.D.	Chief Medical Officer	N/A	N/A	1968

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

Corporate governance

Lyxor Stoxx Eurp 600 IndGd&Sv ETF AccA/I’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.